GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » PS Ratio
中文

Verona Pharma (Verona Pharma) PS Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Verona Pharma's share price is $15.24. Verona Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Verona Pharma's PS Ratio for today is .

The historical rank and industry rank for Verona Pharma's PS Ratio or its related term are showing as below:

During the past 13 years, Verona Pharma's highest PS Ratio was 4211.67. The lowest was 6.05. And the median was 2206.67.

VRNA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.98
* Ranked among companies with meaningful PS Ratio only.

Verona Pharma's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Verona Pharma was -100.00% per year.

Back to Basics: PS Ratio


Verona Pharma PS Ratio Historical Data

The historical data trend for Verona Pharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma PS Ratio Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 9.94 3,732.86 -

Verona Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,732.86 3,346.67 3,523.33 2,716.67 -

Competitive Comparison of Verona Pharma's PS Ratio

For the Biotechnology subindustry, Verona Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Verona Pharma's PS Ratio falls into.



Verona Pharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Verona Pharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.24/0
=

Verona Pharma's Share Price of today is $15.24.
Verona Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Verona Pharma  (NAS:VRNA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Verona Pharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Verona Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.
Executives
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David R Ebsworth director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Kathleen A. Rickard officer: Chief Medical Officer C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Christina Ackermann director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Claire Poll officer: General Counsel C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn officer: Chief Financial Officer 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli director, officer: President and CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc 10 percent owner 730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE